Nice call! Your $96K prediction for the US price of 12 weeks of Sovaldi + Ledipasvir couldn’t possibly have been more accurate, given the pseudo disclosure on pricing that GILD just made.
In my ENTA valuation model, I’m sticking with $60K for the US ASP of ABBV/ENTA’s 3-DAA regimen, as discussed in #msg-94993406. This is a 6% discount relative to the list price of GILD’s 8-week S+L regimen and a 37.5% discount relative to the list price of GILD’s 12-week regimen. (If GILD offers significant rebates on the 8w regimen, I would expect ABBV to match them, maintaining a 5-10% discount for the ASP.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.